Don’t wait, reserve your spot at the first Patient-Centered CMT Summit! There are only 40 spots left. Go to www.cmtsummit.org to reserve your spot now.
With respect to CMT, Dr. Baker’s team has collaborated with Drs. Michael Sereda and Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to utilize their CMT1A transgenic rat and established the initial CMT1A rat colony in the United States.
Dr. Steven J. Gray is an Assistant Professor in the Dept. of Ophthalmology, U. of N. Carolina at Chapel Hill.
Bernadette Scarduzio – a CMT patient and advocate! I reside in Drexel Hill, PA with my 2 dogs.
John is Founder and Managing Director of Infusion Pharma Consulting LLC, a leading business strategy consultancy focused on the Orphan Drug and Hospital Therapeutics
Dr. Liu shares the consensus that CMT is a lesser known disease and more research is needed to shed light on the experiences of patients with CMT.
After her genetic diagnosis, Joy connected with HNF for advice on AFOs and a letter writing campaign to tell family and friends about her diagnosis.
Allison Moore founded HNF in 2001 in an effort to improve the quality of life for people with Charcot-Marie-Tooth.
HNF has invited Dr. Coté to lead the discussion on Public Policy. We will cover issues such as better AFO (leg-bracing) options, fast-tracking drug discoveries and clinical trials, applying for disability benefits, Medicare/Medicaid and services.
We’ve invited Dr. David Walk to join the panel discussion on “Genotype and Phenotype: Managing Symptoms, The Role of Researchers/Clinicians.”
Leaders in Charcot-Marie-Tooth research need to be progressive visionaries, willing and able to push the boundaries to explore every opportunity available to advance therapeutics and clinical trials for CMT.
0 Comments